Literature DB >> 11837725

Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans.

Anna M Buchner1, Amnon Sonnenberg.   

Abstract

The Patient Treatment File (PTF) of the Department of Veterans Affairs (VA) comprises the computerized records of all inpatients treated at all VA hospitals throughout the United States. The database was utilized to study the clinical epidemiology and impact of C. difficile colitis on health care among hospitalized US military veterans. The computerized medical records of 15,091 cases with C. difficile colitis and 61,931 controls without the diagnosis were extracted from the annual files between 1993 and 1998. Of all patients admitted to the hospital, 1% were diagnosed with C. difficile colitis, in 16% of whom it was listed as the primary discharge diagnosis. C. difficile colitis was more likely to occur in elderly white patients with multiple comorbid conditions. Compared with a control population of hospitalized patients without C. difficile colitis, the case population was subjected to more medical and surgical procedures and experienced longer hospital stays. The diagnosis of C. difficile colitis was associated with more frequent admissions to the intensive care unit and higher hospital-related and subsequent mortality. Eleven percent of the cases were admitted to hospital a second time after a mean of 202 days, 2.5% were readmitted a third time after an additional 182 days, and 0.8% were readmitted a fourth time after an additional 194 days. In conclusion, as old age, multiple comorbid conditions, a high number of medical and surgical intervention, and long hospitalization constitute the main risk factors for the development of C. difficile colitis, efforts at prevention should be directed primarily towards patients who present with these characteristics.

Entities:  

Mesh:

Year:  2002        PMID: 11837725     DOI: 10.1023/a:1013252528691

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Celiac sprue among US military veterans: associated disorders and clinical manifestations.

Authors:  F Delcò; H B El-Serag; A Sonnenberg
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

Review 2.  Pseudomembranous colitis: causes and cures.

Authors:  C M Surawicz; L V McFarland
Journal:  Digestion       Date:  1999 Mar-Apr       Impact factor: 3.216

Review 3.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

4.  A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.

Authors:  O Karlström; B Fryklund; K Tullus; L G Burman
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 5.  Clostridium difficile-associated diarrhea and colitis: clinical manifestations, diagnosis, and treatment.

Authors:  R K Cleary
Journal:  Dis Colon Rectum       Date:  1998-11       Impact factor: 4.585

6.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

7.  Epidemiology of community-acquired Clostridium difficile-associated diarrhea.

Authors:  L R Hirschhorn; Y Trnka; A Onderdonk; M L Lee; R Platt
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

8.  Clostridium difficile: an update on its epidemiology and role in hospital outbreaks in England and Wales.

Authors:  T Djuretic; P G Wall; J S Brazier
Journal:  J Hosp Infect       Date:  1999-03       Impact factor: 3.926

9.  Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

Authors:  M B Kimmey; G W Elmer; C M Surawicz; L V McFarland
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

Review 10.  Clinical impact and associated costs of Clostridium difficile-associated disease.

Authors:  R C Spencer
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

View more
  8 in total

1.  Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Andrew E Simor; Alex Kopp; Paula A Rochon; David N Juurlink
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Complicated fecal microbiota transplantation in a tetraplegic patient with severe Clostridium difficile infection.

Authors:  Thorsten Brechmann; Justyna Swol; Veronika Knop-Hammad; Jörg Willert; Mirko Aach; Oliver Cruciger; Wolff Schmiegel; Thomas A Schildhauer; Uwe Hamsen
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions.

Authors:  V K Viswanathan; M J Mallozzi; Gayatri Vedantam
Journal:  Gut Microbes       Date:  2010-06-16

Review 4.  Clostridium Difficile Infection from a Surgical Perspective.

Authors:  Andreas M Kaiser; Rachel Hogen; Liliana Bordeianou; Karim Alavi; Paul E Wise; Ranjan Sudan
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

5.  Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward.

Authors:  A H Gifford; K B Kirkland
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

6.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

7.  Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis.

Authors:  Kirk Ludwig; Eugene R Viscusi; Bruce G Wolff; Conor P Delaney; Anthony Senagore; Lee Techner
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

8.  Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK.

Authors:  J A Chris Delaney; Sandra Dial; Alan Barkun; Samy Suissa
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.